Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which mimics a hormone that helps regulate appetite and food intake, contributing to weight loss.
Cigna's coverage for Wegovy can vary based on the specifics of individual health plans, so it's essential to review the plan details to determine eligibility.
Also worth reading: What types of coverage does Farm Bureau home insurance provide? · What are the most common AI insurance policy exclusions and how can businesses avoid coverage gaps? · Is e-bike insurance required like car insurance in 2026, and how do the coverage differences compare?
Prior authorization is typically required for Wegovy under Cigna plans, meaning that healthcare providers need to demonstrate medical necessity before coverage is granted.
Wegovy is indicated for adults with obesity (BMI of 30 or higher) or with overweight (BMI of 27 or higher) and at least one weight-related comorbidity, such as type 2 diabetes.
The medication is administered via subcutaneous injection, and the recommended maintenance dose is 2.4 mg once weekly after an initial dose escalation over 16 weeks.
The GLP-1 receptor agonists, including Wegovy, may cause gastrointestinal side effects such as nausea, vomiting, and diarrhea, particularly during the initial treatment phase.
Insurance policies like Cigna's may classify Wegovy under specific tiers, which can affect out-of-pocket costs; Wegovy is often placed in a higher tier, leading to higher copayments.
Coverage for weight loss medications is generally limited across many health plans, with some excluding them outright unless deemed medically necessary, which can complicate access to drugs like Wegovy.
Wegovy's mechanism of action includes slowing gastric emptying and increasing feelings of fullness, which can lead to reduced caloric intake over time.
Studies have shown that patients using Wegovy, in conjunction with lifestyle changes, can achieve significant weight loss, with some individuals losing up to 15% of their initial body weight over 68 weeks.
Cigna may consider exceptions for coverage on a case-by-case basis if patients have tried alternative weight loss medications without success.
The use of GLP-1 receptor agonists for weight management is supported by clinical guidelines, as they have shown efficacy in reducing weight and improving metabolic health.
Semaglutide, the active ingredient in Wegovy, was originally developed for the treatment of type 2 diabetes under the brand name Ozempic, and its weight management properties were discovered subsequently.
As of 2025, ongoing research continues to explore the long-term safety and effectiveness of GLP-1 receptor agonists for weight management, including their potential cardiovascular benefits.
Cigna’s policies on medications like Wegovy may evolve based on emerging clinical evidence, economic factors, and changing guidelines from health organizations.
The annual cost of Wegovy can be substantial, often exceeding several thousand dollars, which emphasizes the importance of understanding insurance coverage and potential savings programs.
The pharmacokinetics of semaglutide indicate a half-life of approximately one week, allowing for once-weekly dosing, which can enhance patient compliance compared to daily medications.
Individuals considering Wegovy should engage in a comprehensive treatment plan that includes nutritional counseling and physical activity, as these factors significantly influence treatment outcomes.
Data from clinical trials indicate that weight maintenance after discontinuation of Wegovy can be challenging, and ongoing support may be necessary to sustain weight loss achieved during treatment.
The rise of GLP-1 receptor agonists like Wegovy has prompted discussions around obesity management as a chronic disease, highlighting the need for comprehensive healthcare strategies that address this public health issue.